case_images: PMC7154272_01
case_images: CT scan before radiotherapy: local recurrence of melanoma, 36.80 x 26.78 mm in size, in the nasal cavity (A). MRI at 2 months after IMRT treatment: regression of the tumor (B).
case_images: cro-0013-0271-g01.jpg
case_images: PMC7154272_01_cro-0013-0271-g01.jpg
case_images: F1
case_images: Twenty-one months after the administration of pembrolizumab monotherapy, follow-up computed tomography (CT) scan revealed the local recurrence of melanoma, 36.80 x 26.78 mm in size, in the nasal cavity (Fig. 1A). Two months after the radiotherapy, magnetic resonance imaging (MRI) revealed regression of the tumor (Fig. 1B).
case_images: PET-CT image: metastasis at the scapula before (A) and after (B) combination therapy.
case_images: cro-0013-0271-g02.jpg
case_images: PMC7154272_01_cro-0013-0271-g02.jpg
case_images: F2
case_images: However, 3 months after tumor regression, follow-up positron emission tomography (PET)-CT revealed multiple metastases in the lungs, scapula, and subcutaneous lesions (Fig. 2A). Three months after the first administration of nivolumab plus ipilimumab combination therapy, the multiple metastases in the lungs, scapula, and subcutaneous lesions had regressed (Fig. 2B).